Live Discussion: AI and Precision Medicine in Solid Tumors
Join Dr. Anitha Singareddy, Dr. Andrew Patterson, and Dr. Gabrielle Baxter during a live discussion about blinded independent central review in oncology clinical trials and volumetrics and radiomics in solid tumors.
In this live discussion, IAG’s imaging experts will share their experience in delivering central review in oncology clinical trials, reader performance monitoring, and factors leading to site central discordance. Our experts will cover different radiographic response assessment criteria, such as RECIST 1.1, irRECIST, Choi etc.
Join our live discussion with experts on how to incorporate an efficient imaging strategy and volumetrics and radiomics into drug development programs.
Key discussion points:
- Imaging endpoints in oncology and regulatory requirements
- Site vs central reading: benefits, challengers, and opportunities
- Assessment criteria in solid tumors: choosing the right criteria
- Volumetrics and radiomics in solid tumors
Dr. Anitha Singareddy
Dr. Singareddy is a board-certified physician having more than 13 years of experience in clinical research, CRO industry and medical imaging as well as extensive experience in medical imaging in the solid tumour portfolio using RECIST 1.1, iRECIST and other oncology review criteria.
Dr. Andrew Patterson
Dr. Patterson has experience in selecting optimal imaging and AI strategies to accelerate drug development. Dr. Patterson is an active researcher with over 70 papers focusing on the development of novel imaging biomarkers.
With 20+ years of expertise in radiologic cross-sectional imaging, Julia has in-depth expertise in clinical trial design, advising life science companies how to use imaging-based markers to accelerate their drug development and ensure standardized imaging across multi-center trials.